CytoSorbents Announces Trauma Advisory Board

CytoSorbents Announces Trauma Advisory Board

MONMOUTH JUNCTION, N.J., April 8, 2013 (GLOBE NEWSWIRE) -- CytoSorbents
Corporation (OTCBB:CTSO), a critical care focused company using blood
purification to treat life-threatening illnesses, today announced the
establishment of its Trauma Advisory Board consisting of international leaders
in the fields of trauma, trauma research, and critical care.  Most are
investigators on the Inflammation and the Host Response Glue Grant, a
large-scale multi-disciplinary research program funded by the National
Institute of General Medical Sciences (NIGMS), a division of the National
Institutes of Health.A wealth of information on this program, and the role
that uncontrolled inflammation plays on poor outcome in trauma and burn injury
can be found at:http://www.gluegrant.org/index.htm

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, "As we
continue to expand the potential critical care applications of our CytoSorb®
blood purification technology into burn injury and trauma, we are honored to
have the support of an outstanding group of world-renowned clinicians and
researchers in these fields to help guide us.Their international leadership,
extensive clinical expertise, and understanding of the inflammatory response
in trauma and burn injury will be invaluable as we expand into these fields
through our collaboration with the US Army via $1.1M in SBIR funding awards,
work with trauma surgeons and physicians around the world, and new research
opportunities."

The esteemed members of the CytoSorbents Trauma Advisory Board are:

Dr. Ronald V. Maier, MD – Chairman of the Trauma Advisory Board - is the Jane
and Donald D. Trunkey Endowed Chair in Trauma Surgery and Director of the
Trauma, Burn and Critical Care Division at the Harborview Medical Center at
the University of Washington School of Medicine. Also known as the Northwest
Regional Trauma Center, it is the only Level 1 trauma center in the region
serving Washington, Alaska, Montana and Idaho. Dr. Maier is a trauma surgeon
and researcher, specializing in trauma and critical care surgery, with more
than 250 publications and manuscripts. Dr. Maier's long-standing interest in
trauma has involved extensive clinical studies in the acute management of the
severely injured and critically ill patient. He has also published extensively
on the role of an aberrant host immuno-inflammatory response, including the
role of inflammatory mediators such as cytokines, on the development of
multiple organ dysfunction syndrome and organ failure in trauma. As a Glue
Grant principal investigator, he has also led many clinical trials to
establish treatment guidelines and best practices in trauma. Dr. Maier is
Past-President of the American Association for the Surgery of Trauma, the
International Association for the Surgery of Trauma and Surgical Intensive
Care (which publishes the World Journal of Surgery), the Surgical Infection
Society, the Society of University Surgeons, and the Shock Society. Dr. Maier
has been a fellow of the American Association for the Advancement of Science
since 1994. Dr. Maier has also served as chair and a member of the NIH
Surgery, Anesthesiology and Trauma Study Section, and is past Director and
Chair of the American Board of Surgery. Dr. Maier graduated from the Duke
University School of Medicine in 1973, completed his surgical residency from
the Department of General Surgery at University of Washington, and completed a
postdoctoral fellowship in immunopathology at the Scripps Clinic and Research
Foundation.

Dr. Mitchell Cohen, MD is Associate Professor of Surgery in the Division of
General Surgery at the University of California, San Francisco (UCSF) School
of Medicine, specializing in critical care medicine. Dr. Cohen is also
Director of Acute Care Research at the San Francisco Injury Center. Dr. Cohen
received his MD from the Mount Sinai School of Medicine in 1997 and completed
his surgical residency at Rush University/Cook County Medical Center. Dr.
Cohen completed fellowships at Loyola University Medical Center Burn and Shock
Trauma Institute, and a separate Trauma and Critical Care Fellowship from
UCSF-San Francisco General Hospital. Dr. Cohen has an active basic science
research lab where he studies coagulation and inflammation perturbations after
trauma. In addition he is actively involved in the CDC San Francisco Injury
Center as well as NIH and DoD funded projects related to inflammatory lung
injury and monitoring of resuscitation and coagulation after injury.

Dr. Raul Coimbra, MD, PhD is the Monroe E. Trout Professor of Surgery and
Executive Vice-Chairman of the Department of Surgery at the University of
California, San Diego (UCSD) School of Medicine. Dr. Coimbra is also Chief of
the Division of Trauma, Surgical Critical Care and Burns at UCSD Medical
Center. Among his many appointments, Dr. Coimbra currently serves as President
of the World Coalition for Trauma Care, is Vice-Chair of the American College
of Surgeons Committee on Trauma, and is the Recorder and Chair of the
Scientific Program Committee of the American Association for the Surgery of
Trauma. Dr. Coimbra is an author on more than 350 publications, is on the
Editorial Board of the Journal of Trauma, World Journal of Surgery,
Pan-American Journal of Trauma, World Journal Emergency Surgery, European
Journal of Trauma and Emergency Surgery (Associate Editor) and is an ad-hoc
reviewer of scientific articles for the Annals of Surgery, Critical Care
Medicine, International Pharmacology, Experimental Biology and Medicine,
Archives of Surgery, and others. Dr. Coimbra has been involved in multiple
clinical studies and conducted basic research in the area of trauma, traumatic
brain injury, post-traumatic organ failure, resuscitation, and many others. He
received his MD and PhD from Santa Casa School of Medicine in Sao Paulo,
Brazil in 1985, where he also completed his residency training in General and
Peripheral Vascular Surgery in the Department of Surgery.

Dr. Ernest E. Moore, MD is currently Editor of the Journal of Trauma and Acute
Care Surgery, and was the Chief of Trauma at the Denver General Hospital for
the past 35 years, and Chief of Surgery for the past 26 years.He continues to
serve as Vice Chairman for Research and Professor of Surgery at the University
of Colorado Denver and was the Bruce M. Rockwell Distinguished Chair in Trauma
Surgery.Under Dr. Moore's leadership, the Rocky Mountain Regional Trauma
Center at Denver General became internationally recognized for innovative care
of the injured patient, and its trauma research laboratory has been funded by
the NIH for 25 consecutive years.Dr. Moore has served as president of nine
academic societies, including the Society of University Surgeons, American
Association for the Surgery of Trauma, International Association for the
Surgery of Trauma, and the World Society of Emergency Surgery. Some of his
awards include the Robert Danis Prize from the Society of International
Surgeons, Orazio Campione Prize from the World Society of Emergency Surgery,
and the Lifetime Achievement Award for Resuscitation Science from the American
Heart Association. He has honorary fellowship in the Royal College of Surgeons
– Edinburgh and the American College of Emergency Physicians and is an
honorary member of the Eastern Association for the Surgery of Trauma,
Brazilian Trauma Society, Colombian Trauma Society, and Trauma Association of
Canada. Dr. Moore is editor of the textbook Trauma, now in its 7^th edition,
has more than 1350 publications, and has lectured extensively throughout the
world.

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused therapeutic device company
using blood purification to modulate the immune system and fight multi-organ
failure in life-threatening illnesses.Its purification technology is based on
biocompatible, highly porous polymer beads that can actively remove toxic
substances from blood and other bodily fluids by pore capture and
adsorption.CytoSorb®, the Company's flagship product, is approved in the
European Union as a safe and effective extracorporeal cytokine filter,
designed to reduce the "cytokine storm" that could otherwise cause massive
inflammation, organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis.These are
conditions where the mortality is extremely high, yet no effective treatments
exist.Additional information is available for download on the Company's
website: http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein.Risk factors are detailed
in the Company's Form 10-K filed with the SEC on April 3, 2013, which is
available athttp://www.sec.gov.

CONTACT: Company Contact:
         CytoSorbents Corporation
         Dr. Phillip Chan
         Chief Executive Officer
         (732) 329-8885 ext. *823
         pchan@cytosorbents.com
        
         Investor Contact:
         Alliance Advisors, LLC
         Alan Sheinwald
         (914) 669-0222
         asheinwald@allianceadvisors.net
        
         Valter Pinto
         (914) 669-0222 x201
         valter@allianceadvisors.net
        
         Media Contact:
         JQA Partners
         Jules Abraham
         (917) 885-7378
         jabraham@jqapartners.com